Atlas Trials

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Clinical trial NCT00085696 · COMPLETED

Trial details

NCT number
NCT00085696
Sponsor
Millennium Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
B-Cell LymphomaFollicular LymphomaMarginal Lymphoma
Start date
2004-05-01
Primary completion
2006-04-01
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.